Brief: Processa Pharmaceuticals Announces First Patient Dosed In 300 Mg Dose Group With Next Gen Chemotherapy-Capecitabine

Processa Pharmaceuticals

17/03/2023 13:20

March 17 (Reuters) - Processa Pharmaceuticals Inc
 PCSA.O :
    * PROCESSA PHARMACEUTICALS ANNOUNCES FIRST PATIENT DOSED IN
THE
300 MG DOSE GROUP WITH NEXT GENERATION CHEMOTHERAPY-CAPECITABINE
    * PROCESSA PHARMACEUTICALS INC - IN MID-APRIL PROCESSA
EXPECTS
GUIDANCE FROM FDA ON OUR PHASE 2B TRIAL DESIGN AND OUR PROJECT
OPTIMUS APPROACH

Source text for Eikon:  ID:nGNXbqrZtf 
Further company coverage:  PCSA.O 

 ((Reuters.Briefs@thomsonreuters.com;))